Amphastar Pharmaceuticals Posts FY 2025 Results as Baqsimi Integration Peaks
Key Takeaways
- Amphastar Pharmaceuticals (AMPH) has released its financial results for the fourth quarter and full year of 2025, marking a critical milestone in its transition toward a proprietary-led product portfolio.
- The results highlight the continued performance of Baqsimi and Primatene Mist as the primary drivers of the company's revenue growth and margin expansion.
Key Intelligence
Key Facts
- 1Amphastar reported full-year 2025 results on February 26, 2026, covering the period ending December 31, 2025.
- 2The fiscal year 2025 represents the first full year of optimized commercial control over Baqsimi following its acquisition from Eli Lilly.
- 3Primatene Mist remains the only FDA-approved OTC epinephrine inhaler, serving as a core revenue driver.
- 4The company continues to advance a complex R&D pipeline focused on biosimilar insulin and inhalation products.
- 5Amphastar maintains a strategic focus on high-barrier-to-entry injectables and respiratory medications.
Amphastar Pharmaceuticals
Company- Ticker
- AMPH
- Headquarters
- Rancho Cucamonga, CA
- Key Products
- Baqsimi, Primatene Mist, Epinephrine
A specialty pharmaceutical company focused on developing, manufacturing, and marketing proprietary and generic injectable, inhalation, and intranasal products.
Analysis
Amphastar Pharmaceuticals (NASDAQ: AMPH) officially reported its financial results for the fourth quarter and the full fiscal year ended December 31, 2025, on February 26, 2026. This reporting cycle is particularly significant for the California-based specialty pharmaceutical company, as it represents the first full fiscal year of optimized operations following the total integration of Baqsimi, the nasal glucagon treatment acquired from Eli Lilly. The transition from a company primarily known for high-barrier generics to one defined by high-margin proprietary products has been the central narrative for Amphastar throughout 2025, and these results serve as the definitive scorecard for that strategic pivot.
The core of Amphastar’s growth strategy in 2025 has been the aggressive commercialization of its proprietary portfolio, led by Baqsimi and Primatene Mist. Baqsimi, which Amphastar acquired in a deal valued at up to $1.075 billion in 2023, has transformed the company’s revenue profile. By taking over the global commercial rights from Eli Lilly, Amphastar has been able to focus on market share expansion in the emergency glucagon space, competing directly with traditional injectable kits. Analysts have closely watched the 2025 performance to see if Amphastar could maintain the product's momentum outside of the Lilly ecosystem, and the year-end results suggest a successful handoff with sustained demand in both domestic and international markets.
Baqsimi, which Amphastar acquired in a deal valued at up to $1.075 billion in 2023, has transformed the company’s revenue profile.
Simultaneously, Primatene Mist—the only FDA-approved over-the-counter (OTC) epinephrine inhaler for the temporary relief of mild symptoms of intermittent asthma—continues to be a reliable cash flow engine. Throughout 2025, Amphastar leveraged its unique position in the OTC respiratory market to drive consistent sales, benefiting from a lack of direct generic competition in the retail space. This product, alongside the company’s portfolio of essential hospital injectables like epinephrine and lidocaine, provides a diversified revenue base that mitigates the risks typically associated with single-product pharmaceutical firms.
What to Watch
Beyond the immediate financial metrics, the FY 2025 report underscores Amphastar’s commitment to its long-term R&D pipeline. The company has been investing heavily in complex generic and biosimilar candidates, most notably its insulin pipeline. With the FDA’s increasing focus on biosimilar competition to lower drug prices, Amphastar’s progress with AMP-004 (insulin aspart) and other biosimilar products remains a key area of interest for institutional investors. The 2025 results reflect the balancing act the company must perform: funding expensive clinical trials and regulatory filings for complex biosimilars while maintaining the profitability of its current commercial lineup.
Looking ahead, the market impact of these results will likely center on Amphastar’s ability to manage its debt-to-equity ratio following the Baqsimi acquisition while continuing to return value to shareholders. The company’s focus on high-barrier-to-entry products—those that require specialized manufacturing capabilities like inhalation or injectable technologies—creates a competitive moat that is difficult for smaller generic players to cross. As Amphastar enters 2026, the focus will shift toward the next wave of product approvals and the potential for further strategic acquisitions to bolster its proprietary respiratory and emergency medicine franchises.
Sources
Sources
Based on 2 source articles- hawaiitelegraph.comAmphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31 , 2025Feb 27, 2026
- californiatelegraph.comAmphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31 , 2025Feb 26, 2026